# DefEYE Publishes Peer-Reviewed Clinical Data Supporting Biovance 3L Ocular in Pterygium and Ocular Surface Disease

> news · REPORTED · 2026-02-23

DefEYE announced publication of two peer-reviewed articles in Ophthalmology and Therapy and Clinical Optometry highlighting outcomes with Biovance 3L Ocular, the only tri-layer decellularized basement membrane in ocular surgery, demonstrating no recurrences and sutureless, glueless pterygium excision. The publications support growing clinical evidence for its placental-based biologic platform.

About DefEYE, Inc.: DefEYE, Inc. is a privately held Sarasota-based ophthalmic biologics company that holds exclusive rights to the Biovance franchise of decellularized placental-based tissue products used by ophthalmologists and optometrists to treat ocular surface diseases and assist with surgical recovery.

- Company: DefEYE
- Sector: medical_device
- Primary source: https://launchlabpartners.com/2026/02/23/defeye-announces-publication-of-multiple-peer-reviewed-articles-highlighting-use-of-biovance-3l-ocular/

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.